RxDoctor Payments Data

Tonya Fraser, PA

Medical · Charlotte, NCNPI 1508839226

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.4% of the total across 823 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 15.3% — the pattern of someone who eats at a lot of different presentations. Among medical clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$15,541in general payments, 2019–2025

Across 823 payments — averaging $18.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$2K
  • Pfizer$2K
  • Bayer$922
  • AstraZeneca$908
  • Boehringer Ingelheim$734
  • plus $7K from 54 others

What the payments were for

  • Food & beverage$15,44199%
  • Education$1001%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)130$2,372
Novo Nordisk106$1,859
Pfizer84$1,636
Bayer57$922
AstraZeneca40$908
Boehringer Ingelheim35$734
Exact Sciences14$630
Lilly USA, LLC30$578
Astellas Pharma US Inc25$540
Amgen(2 entities)28$421
Takeda Pharmaceuticals U.S.A., Inc.22$370
GSK17$324
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC18$312
Johnson & Johnson15$270
Biohaven Pharmaceutical Holding Company Ltd.16$237
Novartis15$229
Axsome Therapeutics, Inc.11$222
Biohaven Pharmaceuticals, Inc.12$200
Abbott11$186
Esperion Therapeutics, Inc.10$170
Sumitomo Pharma America, Inc.8$156
Xeris Pharmaceuticals, Inc.9$154
Merck8$142
Bausch Health US, LLC8$132
Treace Medical Concepts, Inc.1$121
Paratek Pharmaceuticals, Inc.7$105
Kowa Pharmaceuticals America, Inc.6$102
Eisai Inc.5$92
Idorsia Pharmaceuticals US Inc5$86
Insightec,inc2$85
Amneal Pharmaceuticals LLC4$79
Corcept Therapeutics4$75
Neos Therapeutics, LP4$73
Teva Pharmaceuticals USA, Inc.3$70
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)3$61
Jazz Pharmaceuticals Inc.4$61
Amarin Pharma, Inc.3$61
Daiichi Sankyo Inc.3$60
Arbor Pharmaceuticals, Inc.3$55
Medtronic3$53
Sanofi-aventis U.S. LLC3$52
Shield Therapeutics Inc3$49
Phathom Pharmaceuticals, Inc.3$48
E.r. Squibb & Sons, L.L.C.3$42
Medicure Pharma Inc.1$40
Dexcom, Inc.2$37
Sunovion Pharmaceuticals Inc.2$35
Inspire Medical Systems, Inc.2$35
Mayne Pharma Commercial LLC3$34
Boston Scientific1$28
Ironwood Pharmaceuticals, Inc1$24
Antares Pharma, Inc.1$21
Convatec Inc.1$21
Vyera Pharmaceuticals, LLC1$20
Edwards Lifesciences1$18
Supernus Pharmaceuticals, Inc.1$18
GRT US Holding, Inc.1$17
Currax Pharmaceuticals LLC1$16
Organon1$16
Upsher-smith Laboratories LLC1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,541 in reported general payments places this provider in the 95th percentile of 878 medical providers in North Carolina.

See all medical providers in North Carolina

Medicare billing

Part B allowed, 2024
$43,389
Medicare patients
194
Services billed
706

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide33$38,558
OzempicSemaglutide18$29,184
MounjaroTirzepatide21$23,981
FarxigaDapagliflozin Propanediol22$20,509
JardianceEmpagliflozin14$14,744
Repatha SureclickEvolocumab13$14,356
TrulicityDulaglutide12$12,715
SynthroidLevothyroxine Sodium39$4,112
Nebivolol Hcl14$1,628
Olmesartan Medoxomil101$1,514
Omeprazole69$1,148
Atorvastatin Calcium158$1,013
Duloxetine Hcl55$889
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine13$863
Levothyroxine Sodium102$819

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$1,859$67,74151 claims
Lilly USA, LLCMounjaro, Trulicity$578$36,69633 claims
AstraZenecaFarxiga$908$20,50922 claims
Boehringer IngelheimJardiance$734$14,74414 claims
AbbVieSynthroid$2,372$4,11239 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$79$819102 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 878 medical providers in North Carolina.

Other medical in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →